RXi Pharma Reports Second Quarter 2017 Financial Results And Recent Corporate Highlights

MARLBOROUGH, Mass., Aug. 10, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today reported its financial results for the second quarter ended June 30, 2017, and provided a business update.

"During the first half of 2017, the Company focused on the main elements that can drive progress and value for RXi," said Dr. Geert Cauwenbergh, President, and CEO of RXi Pharmaceuticals.

Back to news